Following publication of an interim analysis in 2020, the data from the phase 3 KEYNOTE-522 study (N Engl J Med 2020;382[9]:810-821) led to approval of pembrolizumab (Keytruda, Merck) as part of a first-line treatment for triple-negative breast cancer (TNBC). Now, extended follow-up out to a median of 75.1 months shows a five-year overall survival (OS) rate of 86.6%, suggesting this therapy is capable of cure in this setting.
“The long-term data further support pembrolizumab plus a